Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer.
Publication/Presentation Date
11-1-2013
Abstract
External beam radiation therapy (EBRT) combined with brachytherapy (BT) is an attractive treatment option for select patients with clinically localized prostate cancer. Either low- or high-dose rate BT may be combined with EBRT ('LDR-BT boost,' 'HDR-BT boost,' respectively). HDR-BT boost has potential theoretical benefits over LDR-BT boost or external beam radiation therapy monotherapy in terms of radiobiology, radiophysics and patient convenience. Based on prospective studies in this review, freedom from biochemical failure (FFBF) rates at 5 years for low-, intermediate- and high-risk patients have generally been 85-100%, 68-97%, 63-85%, respectively; late Radiotherapy and Oncology Group Grades 3 and 4 genitourinary and gastrointestinal toxicities are seen in < 8% of patients. HDR-BT boost is now a relatively well-established treatment modality for certain intermediate-risk and high-risk prostate cancer patients, though limitations exist in drawing conclusions from the currently published studies.
Volume
10
Issue
6
First Page
751
Last Page
763
ISSN
1745-2422
Published In/Presented At
Zaorsky, N. G., Den, R. B., Doyle, L. A., Dicker, A. P., & Hurwitz, M. D. (2013). Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer. Expert review of medical devices, 10(6), 751–763. https://doi.org/10.1586/17434440.2013.841347
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
24195459
Department(s)
Administration and Leadership
Document Type
Article